| Document Date: 2013-11-21 17:58:56
Open Document File Size: 368,02 KBShare Result on Facebook
City Prior / Dublin / Basel / Leipzig / / Company BP / Novartis Pharma AG / 3Novartis Pharma AG / Siew Hwa Ong3 Archimedes Inc. / / Country Switzerland / Germany / United States / Ireland / / Currency CHF / / Facility University of Leipzig / / IndustryTerm model web site / trial protocols / healthcare delivery / treatment protocol / / MedicalCondition hypertension / disease / chronic heart failure / ESRD / stroke / diabetes / cardiovascular disease / myocardial infarction / chronic kidney disease / diseases / non-insulin diabetes / coronary heart disease / end stage renal disease / weeks ESRD / / MedicalTreatment treatment protocol / / Organization Congress / University of Leipzig / / Position White WB / risk driver / representative / General / / Product TC / BP / TNT / / ProvinceOrState Michigan / / Technology same treatment protocol / Simulated trial protocols / SIMULATION / CVD / / URL www.archimedesmodel.com / /
SocialTag |
Estimating the cardiovascular benefits of DPP-4 inhibitors: a simulated study PCV15 C. Andy Schuetz1, Tina Yeung1, Matthias Blüher2, Siew Hwa Ong3